Recently I asked myself what Google and NVIDIA "bought" in healthcare this year.

The honest answer: almost nothing. And that's the real story.

I went through the 2026 data. No blockbuster healthcare acquisitions from either company.

Instead, both are running the same playbook — embed, don't acquire:

🔹 NVIDIA is stacking partnerships, not cap tables: a $1B AI co-innovation lab with Eli Lilly, a hybrid-cloud "AI factory" with Roche for drug discovery and diagnostics, a Parabricks collaboration with liquid-biopsy diagnostics maker Droplet Biosciences, and an NVentures investment in AI scribe company Abridge to train a healthcare-specific clinical model.


🔹 Google/Alphabet launched Health100 with CVS Health — an agentic-AI consumer engagement platform built on Google Cloud — rather than buying a health tech company outright.


Compare that to players like RadNet, which is actively rolling up radiology AI companies (iCAD, Gleamer, See-Mode, CIMAR) to build a diagnostics portfolio.


The pattern: hyperscalers are choosing infrastructure and data access over ownership.

They don't need to own the clinical company — they need the workload running on their chips and cloud. It's a lower-risk, higher-leverage play than M&A, and it lets them scale across dozens of health systems and pharma partners simultaneously instead of integrating one acquisition at a time.

For founders and operators in HealthTech: the door to a "strategic acquisition exit" by Big Tech looks narrower than it did a few years ago. The door to becoming their infrastructure partner is wide open.
What are you seeing in your corner of the ecosystem — acquisition appetite, or partnership appetite?

#healthtech #digitalhealth #aiinhealthcare #nvidia #google #healthcareinnovation